The COVID-19 pandemic has impacted the way many pharmaceutical, biotech, and CRO companies are working, rewarding flexibility and agile resourcing and operating models. In this expert insights blog, we sit down (virtually) with Kelly J. Hill, Executive Director,...
MMS Holdings Expert Insights Blog
Experts at MMS share their insights on trending
topics in the pharmaceutical industry.
Whitepaper: Six Changes that Pharmaceutical Companies Should Consider in Response to COVID-19
[Fill out the form below to access the whitepaper] In the wake of the global pandemic of COVID-19, also known and SARS-COV-2, regulators, health authorities, and lawmakers across the globe have rushed to implement countermeasures and develop best practices to curtail...
Unprecedented does not have to mean unprepared: Business Continuity Planning
During these unprecedented times, many businesses are struggling to continue business as usual while the world is rapidly changing around them; however, certain businesses continue to thrive. Throughout this COVID-19 pandemic, companies like MMS, among other leaders...
The Circle of Concern vs the Circle of Influence: A Conversation with Dr. Uma Sharma
In this Expert Insights interview, we sit down with Dr. Uma Sharma, Chief Scientific Officer at MMS Holdings. Dr. Sharma discusses her thoughts surrounding the Circle of Concern and the Circle of Influence, including how it influences the culture at MMS. Q: Can you...
The New Roaring 20s: 12 Experts Provide Pharmaceutical Insights for the Decade Ahead
The pharmaceutical industry—and healthcare in general—are in constant stages of innovation. According to the International Federation of Pharmaceutical Manufacturers & Associations, the number of new chemical or biological entities launched on the world market...
Webinar: The Programmers Approach to Real World Data and Using Real World Evidence in Research and Healthcare
by MMS Holdings and MichBio.org This webinar is intended to help guide individuals towards a better understanding of core concepts and requirements for using real-world data (RWD). Here, we will delve into how one can derive and utilize real-world evidence (RWE) in...
Planning for Health Canada’s New Transparency Initiatives for Clinical Data
In March 2019, Health Canada created a new transparency requirement. Health Canada’s Public Release of Clinical Information (PRCI) states that their “objective is to make anonymized clinical information in drug submissions and medical device applications publicly...
Pharmaceutical Industry Experts Speak Out: Five Productivity Tips for Working from Home
In the pharmaceutical industry, the right talent can often live in a variety of locations. When talking to our colleagues who have the privilege to work from home (WFH), we found that they are happy, productive, and active contributors to the workplace on a daily...
Using Real World Data in Drug Development: Five Questions with Vijay Ivaturi, PhD
The idea and practice of using real world data in the pharmaceutical industry has driven much conversation as of late. As groups like the Health Analytics Collective begin to bring game-changing methodologies to the marketplace, we sat down with Vijay Ivaturi,...